Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Kenneth Kim, MD

ARK Clinical Research

Disclosure(s): Adagio: Funding; Eli Lilly: Funding; Merck: Funding; Pfizer: Funding; Regeneron: Funding, Speaker

Poster(s):

1918 - Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1924 - Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET